External

Main navigation

CRBLM Symposium on Language and Schizophrenia

Tuesday, June 17, 2025 10:00to15:00

The CRBLM is pleased to present a symposium featuring Professor Heather Sheridan (SUNY Albany), and Professor Veronica Whitford (University of New Brunswick Fredericton), followed by a student data...

Read more about CRBLM Symposium on Language and Schizophrenia

8th National Neuromuscular Review Course

Friday, October 24, 2025 09:00toSaturday, October 25, 2025 17:00

Dr. Nicolas Dupré of Laval University, Dr. Karine Garneau of Université de Montréal, and the members of the organizing committee are pleased to announce the 8th National Neuromuscular Review Course...

Read more about 8th National Neuromuscular Review Course

6th National Course on Sleep Medicine

Friday, November 28, 2025 09:00toSaturday, November 29, 2025 16:00

This two-day training course is designed to provide and enhance a basic working knowledge of sleep medicine.3801 rue University, Montreal, QC, H3A 2B4, CA/neuroCategory: Medicine Research...

Read more about 6th National Course on Sleep Medicine

2025 Hughlings Jackson Lecture: The Basal Ganglia and the Motivation to Act

Thursday, November 13, 2025 16:00to17:00

Established in 1935, the Hughlings Jackson Lecture is The Neuro’s premier scientific lecture. It honours the legacy of British neurologist John Hughlings Jackson (1835-1911) who pioneered the...

Read more about 2025 Hughlings Jackson Lecture: The Basal Ganglia and the Motivation to Act

Feindel Brain and Mind Seminar Series: High Performance Mid-Field MRI - The Synaptive Perspective

Monday, June 2, 2025 10:00to11:00

The Feindel Brain and Mind Seminar Series will advance the vision of Dr. William Feindel (1918–2014), Former Director of the Neuro (1972–1984), to constantly bridge the clinical and research realms...

Read more about Feindel Brain and Mind Seminar Series: High Performance Mid-Field MRI - The Synaptive Perspective

Latest Alzheimer’s drug shown less effective in females than males

Published: 18 March 2025

Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...